Acute Lymphoblastic Leukemia, Leukemia, Non-Hodgkin's Lymphoma
Conditions
Brief summary
The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial.
Interventions
None listed
Sponsors
Goethe University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Acute Lymphoblastic Leukemia (All Subtypes) if treated according to ALL protocols * Other Types of Leukemia (NK Cell Lymphoma/Leukemia, Biphenotypic Acute Leukemia) if treated according to ALL protocols * Non-Hodgkin's Lymphoma of Following Subtypes: Burkitt Lymphoma, B Cell Lymphoma, B- or T-lineage Lymphoblastic Lymphoma, Anaplastic Large Cell Lymphoma, Other NHL) if treated according to B-ALL protocols * Age minimum 18 yrs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | up to 10 years |
Secondary
| Measure | Time frame |
|---|---|
| Event free survival | up to 10 years |
| Hematologic remission rate | after induction and consolidation, approximately 6 - 8 weeks from diagnosis |
| Molecular remission rate | after induction and consolidation, approximately 6 - 8 weeks from diagnosis |
| Positron Emission Tomography (PET) based remission evaluation | after induction and consolidation, approximately 6 - 8 weeks from diagnosis |
| Remission duration | up to 10 years |
| Relapse rate | up to 10 years |
| Disease free survival | up to 10 years |
| Early mortality | during induction therapy with a duration of approximately 6 - 8 weeks |
| Mortality in Clinical Remission (CR) | up to 10 years |
| Comorbidities | Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified |
| Quality of life assessed by Quality of Life Questionnaire (QLQ-C30) | after treatment which is approximately 2.5 years from diagnosis |
| Eastern Cooperative Oncology Group (ECOG) status | Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified |
| Toxicities assessed by CTCAE v4.03 | during treatment with an approximate duration of 2.5 years from diagnosis |
Countries
Austria, Germany
Contacts
CONTACTNicola Gökbuget, Dr. med.
CONTACTGMALL Study center
PRINCIPAL_INVESTIGATORNicola Gökbuget, Dr. med.
University Hospital of Frankfurt (Main)
Outcome results
None listed